Helen M Colhoun

Summary

Affiliation: University of Dundee
Country: UK

Publications

  1. ncbi Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
    H M Colhoun
    Biomedical Research Institute, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK
    Diabetologia 52:1755-65. 2009
  2. ncbi Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial
    Helen M Colhoun
    Medical Research Institute, University of Dundee, Dundee, U K
    Diabetes 60:2379-85. 2011
  3. ncbi Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)
    Helen M Colhoun
    Biomedical Research Institute, University of Dundee, Dundee, Scotland, UK
    Am J Kidney Dis 54:810-9. 2009
  4. ncbi Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
    Harshal A Deshmukh
    University of Dundee, Dundee, United Kingdom
    J Lipid Res 53:1000-11. 2012
  5. ncbi Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study
    Shona J Livingstone
    University of Dundee, Dundee, United Kingdom
    PLoS Med 9:e1001321. 2012

Collaborators

Detail Information

Publications5

  1. ncbi Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
    H M Colhoun
    Biomedical Research Institute, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK
    Diabetologia 52:1755-65. 2009
    ..The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin...
  2. ncbi Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial
    Helen M Colhoun
    Medical Research Institute, University of Dundee, Dundee, U K
    Diabetes 60:2379-85. 2011
    ..We examined the relationship of sRAGE and esRAGE to incident coronary heart disease (CHD) and stroke in type 2 diabetic patients followed for 3.9 years in a trial of atorvastatin: the Collaborative Atorvastatin Diabetes Study (CARDS)...
  3. ncbi Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)
    Helen M Colhoun
    Biomedical Research Institute, University of Dundee, Dundee, Scotland, UK
    Am J Kidney Dis 54:810-9. 2009
    ..We examined whether atorvastatin affects diabetic kidney disease and whether the effect of atorvastatin on cardiovascular disease (CVD) varies by kidney status in patients with diabetes...
  4. ncbi Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
    Harshal A Deshmukh
    University of Dundee, Dundee, United Kingdom
    J Lipid Res 53:1000-11. 2012
    ..Therefore, an apparently lower LDL-c response to statin therapy may indicate a need for measurement of Lp(a). However, statin therapy seems beneficial even in those with high Lp(a)...
  5. ncbi Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study
    Shona J Livingstone
    University of Dundee, Dundee, United Kingdom
    PLoS Med 9:e1001321. 2012
    ..We evaluated these risks in adults with T1DM compared with the non-diabetic population in a nationwide study from Scotland and examined control of CVD risk factors in those with T1DM...